1 546

Cited 74 times in

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

DC Field Value Language
dc.contributor.author이병완-
dc.contributor.author이용호-
dc.date.accessioned2017-11-02T08:05:22Z-
dc.date.available2017-11-02T08:05:22Z-
dc.date.issued2017-
dc.identifier.issn1011-8934-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154061-
dc.description.abstractDespite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. Transient liver elastography (Fibroscan®; Echosens, Paris, France) with controlled attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents. Fifty patients with CAP values above 250 dB/m were treated once daily with 0.5 mg lobeglitazone for 24 weeks. The primary endpoint was a decline in CAP values, and secondary endpoints included changes in components of glycemic, lipid, and liver profiles. Lobeglitazone-treated patients showed significantly decreased CAP values (313.4 dB/m at baseline vs. 297.8 dB/m at 24 weeks; P = 0.016), regardless of glycemic control. Lobeglitazone improved HbA(1C) values (7.41% [57.5 mM] vs. 6.56% [48.2 mM]; P < 0.001), as well as the lipid and liver profiles of the treated patients. Moreover, multivariable linear regression analysis showed that hepatic fat reduction by lobeglitazone was independently associated with baseline values of CAP, liver stiffness, and liver enzymes, and metformin use. Lobeglitazone treatment reduced intrahepatic fat content, as assessed by transient liver elastography, and improved glycemic, liver, and lipid profiles in T2D patients with NAFLD. Further randomized controlled trials using liver histology as an end point are necessary to evaluate the efficacy of lobeglitazone for NAFLD treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT02285205.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisher대한의학회(The Korean Academy of Medical Sciences)-
dc.relation.isPartOfJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBlood Glucose/analysis-
dc.subject.MESHDiabetes Mellitus, Type 2/complications-
dc.subject.MESHDiabetes Mellitus, Type 2/drug therapy*-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHElasticity Imaging Techniques-
dc.subject.MESHFemale-
dc.subject.MESHGlycated Hemoglobin A/analysis-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents/therapeutic use*-
dc.subject.MESHLinear Models-
dc.subject.MESHLipids/blood-
dc.subject.MESHLiver/diagnostic imaging-
dc.subject.MESHMale-
dc.subject.MESHMetformin/therapeutic use-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNon-alcoholic Fatty Liver Disease/complications*-
dc.subject.MESHProspective Studies-
dc.subject.MESHPyrimidines/therapeutic use*-
dc.subject.MESHThiazolidinediones/therapeutic use*-
dc.subject.MESHTreatment Outcome-
dc.titleLobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness-
dc.typeArticle-
dc.publisher.locationKorea (South)-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYong-ho Lee-
dc.contributor.googleauthorJae Hyeon Kim-
dc.contributor.googleauthorSo Ra Kim-
dc.contributor.googleauthorHeung Yong Jin-
dc.contributor.googleauthorEun-Jung Rhee-
dc.contributor.googleauthorYoung Min Cho-
dc.contributor.googleauthorByung-Wan Lee-
dc.identifier.doi10.3346/jkms.2017.32.1.60-
dc.contributor.localIdA02989-
dc.contributor.localIdA02796-
dc.relation.journalcodeJ01517-
dc.identifier.eissn1598-6357-
dc.identifier.pmid27914133-
dc.subject.keywordNon-Alcoholic Fatty Liver Disease-
dc.subject.keywordThiazolidinedione-
dc.subject.keywordTransient Liver Elastography-
dc.subject.keywordType 2 Diabetes-
dc.contributor.alternativeNameLee, Byung Wan-
dc.contributor.alternativeNameLee, Yong Ho-
dc.contributor.affiliatedAuthorLee, Yong Ho-
dc.contributor.affiliatedAuthorLee, Byung Wan-
dc.citation.titleJournal of Korean Medical Science-
dc.citation.volume32-
dc.citation.number1-
dc.citation.startPage60-
dc.citation.endPage69-
dc.identifier.bibliographicCitationJOURNAL OF KOREAN MEDICAL SCIENCE, Vol.32(1) : 60-69, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid41550-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.